Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Solifenacin
Drug ID BADD_D02445
Description Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.[L7511] It has a long duration of action as it is usually taken once daily.[L7511] Solifenacin was granted FDA approval on 19 November 2004.[L7511]
Indications and Usage For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Marketing Status Not Available
ATC Code G04BD08
DrugBank ID DB01591
KEGG ID D08522
MeSH ID D000069464
PubChem ID 154059
TTD Drug ID D0L4YD
NDC Product Code 51248-150; 51248-151; 54868-5398; 54868-4705; 68151-5406; 70518-1866; 50090-0972; 55154-3877; 55154-3878; 54569-5790; 55154-3875; 55154-3876
Brand Vesikur
Synonym Solifenacin Succinate | Succinate, Solifenacin | Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate | YM905 | YM 905 | 905, YM | Vesicare | Solifenacin | 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,1- azabicyclo(2.2.2)oct-3-yl ester, (R-(R*,S*))-
Chemical Information
Molecular Formula C23H26N2O2
CAS Registry Number 242478-37-1
SMILES C1CN2CCC1C(C2)OC(=O)N3CCC4=CC=CC=C4C3C5=CC=CC=C5
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.003--
Accommodation disorder06.02.04.001--Not Available
Acute myocardial infarction24.04.04.001; 02.02.02.001--Not Available
Acute pulmonary oedema02.05.02.004; 22.01.03.005--Not Available
Ageusia17.02.07.001; 07.14.03.003--Not Available
Agitation19.06.02.001; 17.02.05.012--
Agranulocytosis01.02.03.001--Not Available
Alopecia23.02.02.001--
Amnesia19.20.01.001; 17.03.02.001--
Amylase increased13.05.01.009--
Anaemia01.03.02.001--
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Angina pectoris24.04.04.002; 02.02.02.002--
Angioedema23.04.01.001; 10.01.05.009--Not Available
Anticholinergic syndrome17.05.01.001--Not Available
Anuria20.01.03.002--Not Available
Anxiety19.06.02.002--
Aphonia22.02.05.024; 19.19.01.002; 17.02.08.009--
Arrhythmia02.03.02.001--Not Available
Arteriosclerosis coronary artery24.04.04.012; 02.02.01.011--Not Available
Ascites09.01.05.003; 07.07.01.001; 02.05.04.002--
Asthenia08.01.01.001--Not Available
Atrial fibrillation02.03.03.002--
Autoimmune hepatitis10.04.09.001; 09.01.07.019--Not Available
Back pain15.03.04.005--
Basedow's disease10.04.08.004; 06.09.04.003; 05.02.02.003--Not Available
Bladder cancer16.08.01.001; 20.03.04.001--Not Available
Blood glucose increased13.02.02.002--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 7 Pages